Rayner announced its investment into the US market with the establishment of a dedicated subsidiary, Rayner Surgical Inc. Based out of New York, Rayner Surgical will provide US specific marketing, regulatory, commercial, and research functions to Rayner. From its offices at 100 Park Avenue, New York City, Rayner Surgical will actively promote and support the growth and development of Rayner’s business in the United States.
Rayner’s latest lens platform—the 600—has just received FDA approval and will be launched in the US in 2018 in both manual and preloaded formats.
A new, physical presence in the United States will strengthen Rayner’s relationships with US surgeons, universities, and key opinion leaders, generating valuable collaborative partnerships and identifying new opportunities in IOL design and innovation, according to a company news release. Where clinical studies in the US are required, Rayner Surgical will lead in identifying suitable providers, investigators and investigation sites and in study design and management. The highest levels of customer service and greater knowledge of customer requirements is expected to lead to an exciting new IOL product pipeline for the American market, contributing to improvements in visual outcomes for clinicians and patients.
There will be no changes to the sales/order process of Rayner’s existing portfolio of IOLs and injectors.
In September 2017, James Crutchlow relocated to New York from the United Kingdom to manage Rayner Surgical as Director - North America. Mr. Crutchlow is well versed in similar projects having led Rayner’s direct entry into Spain, Italy, and Portugal over the last 2 years, establishing wholly-owned subsidiaries. Mr. Crutchlow has nearly 10 years’ life sciences experience, 9 of which have been at Rayner. He is an MBA candidate at the University of Warwick and holds a BA (Hons) degree from the University of Central Lancashire. As a senior member of Rayner’s commercial team, Mr. Crutchlow can be relied on to deliver the objectives set for growth in the world’s largest IOL market, in accordance with Rayner’s values and its strategic plans.
“Over the last few years, James has done an outstanding job in establishing and developing the Rayner business in countries like Spain and Italy which is growing over 400% year on year," Rayner CEO Tim Clover said in the news release. "I am very pleased that he has agreed to lead the company in this new direction. The investment in our US subsidiary marks a significant achievement in Rayner’s ambitious growth strategy and we will continue to work hard in providing the US market with access to existing products as well as products in our pipeline, all with the ambition of delivering better patient outcomes.”